Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …
ImmTACs for targeted cancer therapy: Why, what, how, and which
J Oates, NJ Hassan, BK Jakobsen - Molecular immunology, 2015 - Elsevier
Overcoming immunosuppression and activating a cytotoxic T cell response has the potential
to halt the progression of cancer and, in some circumstances, eradicate it. Designing …
to halt the progression of cancer and, in some circumstances, eradicate it. Designing …
Stable, soluble T‐cell receptor molecules for crystallization and therapeutics
JM Boulter, M Glick, PT Todorov, E Baston… - Protein …, 2003 - academic.oup.com
Antibody and T‐cell receptors (TCRs) are the primary recognition molecules of the adaptive
immune system. Antibodies have been extensively characterized and are being developed …
immune system. Antibodies have been extensively characterized and are being developed …
Facilitating matched pairing and expression of TCR chains introduced into human T cells
J Kuball, ML Dossett, M Wolfl, WY Ho, RH Voss… - Blood, 2007 - ashpublications.org
Adoptive transfer of T lymphocytes is a promising treatment for a variety of malignancies but
often not feasible due to difficulties generating T cells that are reactive with the targeted …
often not feasible due to difficulties generating T cells that are reactive with the targeted …
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface
The off-rate (k off) of the T cell receptor (TCR)/peptide-major histocompatibility complex class
I (pMHCI) interaction, and hence its half-life, is the principal kinetic feature that determines …
I (pMHCI) interaction, and hence its half-life, is the principal kinetic feature that determines …
Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope
A keystone of antiviral immunity is CD8+ T cell recognition of viral peptides bound to MHC-I
proteins. The recognition modes of individual T cell receptors (TCRs) have been studied in …
proteins. The recognition modes of individual T cell receptors (TCRs) have been studied in …
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
M Andrea, T Weinschenk, V Goldfinger… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …
immunotherapeutic methods. In particular, the present invention relates to the immuno …
The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor ζ chain
MA Purbhoo, JM Boulter, DA Price, AL Vuidepot… - Journal of Biological …, 2001 - ASBMB
Recognition of antigen by cytotoxic T lymphocytes (CTL) is determined by interaction of both
the T cell receptor and its CD8 coreceptor with peptide-major histocompatibility complex …
the T cell receptor and its CD8 coreceptor with peptide-major histocompatibility complex …
Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
M Andrea, T Weinschenk, V Goldfinger… - US Patent …, 2019 - Google Patents
The present invention relates to peptides, proteins, nucleic acids and cells for use in
immunotherapeutic methods. In particular, the present invention relates to the immuno …
immunotherapeutic methods. In particular, the present invention relates to the immuno …
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory …
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has
greatly advanced the treatment of hematological malignancies, reaching meaningful clinical …
greatly advanced the treatment of hematological malignancies, reaching meaningful clinical …